Form D · Biotechnology
Carmell Therapeutics Corp
Pittsburgh, PA · CIK 0001517941
Offering snapshot reported Sep 25, 2020 · SEC filing
- Reported sold
- $2.38M Offering amount: $3.5M
- Investors reported
- 37 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 25, 2019 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$80,000 → $2,384,324
- Reported investors2 → 37
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 25, 2020 | Amendment | $2,384,324 | $2,304,324vs Oct 16, 2019 | 37 | SEC filing |
| Jul 8, 2020 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Oct 16, 2019 | Initial | $80,000 | No comparison | 2 | SEC filing |
| Mar 14, 2019 | Amendment | $5,184,535 | $4,034,535vs Jul 13, 2018 | 44 | SEC filing |
| Jul 13, 2018 | Initial | $1,150,000 | No comparison | 8 | SEC filing |
| Apr 25, 2018 | Amendment | $439,160 | $75,000vs Jan 10, 2018 | 6 | SEC filing |
| Jan 10, 2018 | Initial | $364,160 | No comparison | 5 | SEC filing |
| Dec 6, 2017 | Amendment | $1,967,009 | $1,568,774vs Oct 3, 2017 | 25 | SEC filing |
| Oct 3, 2017 | Initial | $398,235 | No comparison | 4 | SEC filing |
| Apr 14, 2017 | Amendment | $1,055,575 | $288,101vs Jan 9, 2017 | 25 | SEC filing |
| Jan 9, 2017 | Initial | $767,474 | No comparison | 17 | SEC filing |
| Feb 5, 2016 | Initial | $774,853 | No comparison | 8 | SEC filing |
| Aug 4, 2015 | Initial | $137,233 | No comparison | 5 | SEC filing |
| Dec 30, 2014 | Amendment | $556,172 | $252,354vs Nov 12, 2014 | 11 | SEC filing |
| Nov 12, 2014 | Initial | $303,818 | No comparison | 6 | SEC filing |
| Jun 11, 2014 | Amendment | $681,456 | $311,456vs Dec 23, 2013 | 11 | SEC filing |
| Dec 23, 2013 | Initial | $370,000 | No comparison | 5 | SEC filing |
| Dec 14, 2012 | Initial | $410,797 | No comparison | 8 | SEC filing |
| Apr 13, 2011 | Initial | $2,389,228 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $37K
- Finders' fees
- $0
- Form D file number
- 021-351149
Offering consists of $3,200,000 of Convertible Notes and $300,000 of Warrants
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Alere Financial Partners | 109761 |
Source: Form D, filed Sep 25, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David W. Anderson | Director |
| Wendy Di Cicco | Director |
| J. Michael Egan | Director |
| Donna Godward | Executive |
| James Hart | Executive |
| Randolph Hubbell | Director, Executive |
| James F. Jordan | Director |
| Stephanie Kladakis | Executive |
| Paul Kornblith | Director, Executive |
| William Newlin | Director, Executive |
| Richard Upton | Director |
| Alan I. West | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2403 Sidney Street, Suite 300
Pittsburgh, PA, 15203
Pittsburgh, PA, 15203